ClinicalTrials.gg
CompletedNCT03772587Updated Jun 27, 2023Results posted

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

A Phase 2 interventional study of M281 and Placebo in Generalized Myasthenia Gravis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 61 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
47th of 108
68 · median 56
Started
2019
with 13 others
Phase 2
26 of 144
5 open now
Registered
37th of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 47th largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 37th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • M281
  • Generalized Myasthenia Gravis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments.

Additional, more specific criteria are defined in the protocol.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    Other: Placebo

  • Experimental
    Group 2

    Drug: M281

  • Experimental
    Group 3

    Drug: M281

  • Experimental
    Group 4

    Drug: M281

  • Experimental
    Group 5

    Drug: M281

Interventions

  • DrugM281

    M281 administered as IV infusion

  • OtherPlacebo

    Placebo administered as intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability

    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE are defined as any AE occurring during or after the initiation of the first infusion of study drug.

    Time frame: Up to Day 113

  2. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

    Time frame: Up to Day 113

  3. Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)

    An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. For this study, any common terminology criteria for adverse events (CTCAE) Grade 3 or higher event of severe infection or hypoalbuminemia was considered as AESI.

    Time frame: Up to Day 113

  4. Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score

    The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Baseline to Day 57

Secondary outcomes

  1. Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57

    Estimate of additional change from baseline in MG-ADL total score for every 10 percent (%) additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57. The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Baseline and Day 57

  2. Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57

    Estimate of additional change from baseline in MG-ADL total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The MG-ADL was used to assess participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). Total score is sum of eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Baseline and Day 57

  3. Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57

    Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Baseline and Day 57

  4. Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57

    Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Baseline and Day 57

  5. Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score at Day 57

    The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Day 57

  6. Change From Baseline in Total QMG Score at Day 57

    The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Baseline and Day 57

  7. Number of Participants With a 3-, 4-, 5-, 6-, 7-, or >= 8-point Improvement in Total QMG Score at Day 57

    The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Day 57

  8. Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57

    The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

    Time frame: Baseline and Day 57

  9. Change From Baseline in Total Serum IgG at Day 57

    Change from baseline in total serum IgG was reported. Blood samples were collected for analysis of total serum IgG.

    Time frame: Baseline and Day 57

  10. Change From Baseline in Total MG-ADL Score at Day 85 and Day 113

    The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Baseline, Day 85 and Day 113

  11. Change From Baseline in Total QMG Score at Day 85 and Day 113

    The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Baseline, Day 85 and Day 113

  12. Change From Baseline in Total MG-QoL15r Score at Day 85 and Day 113

    The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

    Time frame: Baseline, Day 85 and Day 113

  13. Number of Participants With Shift From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification at Day 57

    The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

    Time frame: Baseline and Day 57

  14. Number of Participants With Shift From Baseline in MGFA Classification to Day 113

    The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

    Time frame: Baseline to Day 113

  15. Change From Baseline in Total Serum IgG at Day 85 and Day 113

    Change from baseline in total serum IgG at Day 85 and Day 113 was analyzed. Blood samples were collected for analysis of total serum IgG.

    Time frame: Baseline, Day 85 and Day 113

  16. Serum Concentrations of Nipocalimab

    Serum concentrations of nipocalimab were reported. Concentrations below the lowest quantifiable concentration (\< LLOQ) that is \<0.15 microgram/milliliter (mcg/mL) was treated as zero in calculating the summary statistics.

    Time frame: Baseline (Pre Infusion and Post Infusion), Day 15 (Pre Infusion), Day 29 (Pre Infusion), Day 43 (Pre Infusion), Day 57 (Pre Infusion and Post Infusion) and Day 85

07

Results

Posted Oct 27, 2021
Limitations and caveats
Limitations to this study include the small sample sizes of each treatment arm and the study activity disruption due to the COVID-19 pandemic, especially the missed Quantitative Myasthenia Gravis (QMG) assessments which hampered the analysis of the endpoint.

Participant flow

Participant flow — Overall Study
MilestonePlaceboNipocalimab (M281) 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Started1414131314
Completed1314121214
Not completed10110
Withdrew: Covid-1900110
Withdrew: Withdrawal by subject10000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE are defined as any AE occurring during or after the initiation of the first infusion of study drug.

Time frame:
Up to Day 113
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability
ParticipantsPlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability111291212
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs)

An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

Time frame:
Up to Day 113
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)20100
PrimaryNumber of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)

An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. For this study, any common terminology criteria for adverse events (CTCAE) Grade 3 or higher event of severe infection or hypoalbuminemia was considered as AESI.

Time frame:
Up to Day 113
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)00000
PrimaryChange From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score

The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Baseline to Day 57
Reported as:
Mean · score on a scale
Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score
score on a scalePlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score-1.8 ± 3.22-2.5 ± 2.41-3.9 ± 3.00-1.5 ± 2.82-3.9 ± 3.66
SecondaryChange From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57

Estimate of additional change from baseline in MG-ADL total score for every 10 percent (%) additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57. The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Baseline and Day 57
Reported as:
Least squares mean · score on a scale per 10% IgG reduction
Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57
score on a scale per 10% IgG reductionPlacebo/Nipocalimab (All Participants)
Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57-0.30 ± 0.136
SecondaryChange From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57

Estimate of additional change from baseline in MG-ADL total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The MG-ADL was used to assess participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). Total score is sum of eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Baseline and Day 57
Reported as:
Least squares mean · score on a scale per 10% IgG reduction
Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
score on a scale per 10% IgG reductionPlacebo/Nipocalimab (All Anti-AChR Positive Participants)
Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57-0.33 ± 0.144
SecondaryChange From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57

Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Baseline and Day 57
Reported as:
Least squares mean · score on a scale per 10% IgG reduction
Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57
score on a scale per 10% IgG reductionPlacebo/Nipocalimab (All Participants)
Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57-0.38 ± 0.174
SecondaryChange From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57

Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Baseline and Day 57
Reported as:
Least squares mean · score on a scale per 10% IgG reduction
Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
score on a scale per 10% IgG reductionPlacebo/Nipocalimab (All Anti-AChR Positive Participants)
Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57-0.45 ± 0.181
SecondaryNumber of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score at Day 57

The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Day 57
Reported as:
Count of participants · Participants
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score at Day 57
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
2-point Improved7910712
3-point Improved598511
4-point Improved15537
5-point Improved12526
6-point Improved11313
7-point Improved11302
>=8-point Improved10102
SecondaryChange From Baseline in Total QMG Score at Day 57

The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Baseline and Day 57
Reported as:
Mean · score on a scale
Change From Baseline in Total QMG Score at Day 57
score on a scalePlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Change From Baseline in Total QMG Score at Day 57-3.7 ± 2.94-3.5 ± 4.10-4.1 ± 3.45-1.5 ± 2.54-5.9 ± 5.30
SecondaryNumber of Participants With a 3-, 4-, 5-, 6-, 7-, or >= 8-point Improvement in Total QMG Score at Day 57

The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Day 57
Reported as:
Count of participants · Participants
Number of Participants With a 3-, 4-, 5-, 6-, 7-, or >= 8-point Improvement in Total QMG Score at Day 57
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
3-point Improved866410
4-point Improved556310
5-point Improved55518
6-point Improved25415
7-point Improved25103
>= 8-point Improved23103
SecondaryChange From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57

The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

Time frame:
Baseline and Day 57
Reported as:
Mean · score on a scale
Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57
score on a scalePlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57-2.0 ± 4.58-1.7 ± 4.16-6.8 ± 5.73-1.2 ± 1.91-3.7 ± 5.37
SecondaryChange From Baseline in Total Serum IgG at Day 57

Change from baseline in total serum IgG was reported. Blood samples were collected for analysis of total serum IgG.

Time frame:
Baseline and Day 57
Reported as:
Mean · gram/liter (g/L)
Change From Baseline in Total Serum IgG at Day 57
gram/liter (g/L)PlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Change From Baseline in Total Serum IgG at Day 57-0.3 ± 1.82-1.5 ± 1.01-3.4 ± 1.01-1.7 ± 1.23-7.6 ± 2.27
SecondaryChange From Baseline in Total MG-ADL Score at Day 85 and Day 113

The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Baseline, Day 85 and Day 113
Reported as:
Mean · score on a scale
Change From Baseline in Total MG-ADL Score at Day 85 and Day 113
score on a scalePlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Day 85-2.2 ± 2.64-2.1 ± 2.40-3.7 ± 2.69-1.9 ± 2.29-3.6 ± 2.79
Day 113-2.6 ± 3.09-1.0 ± 2.25-2.8 ± 2.33-2.4 ± 2.78-2.6 ± 3.30
SecondaryChange From Baseline in Total QMG Score at Day 85 and Day 113

The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Baseline, Day 85 and Day 113
Reported as:
Mean · score on a scale
Change From Baseline in Total QMG Score at Day 85 and Day 113
score on a scalePlaceboNipocalimab 5 Milligram/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Day 85-4.0 ± 2.62-3.6 ± 3.23-4.8 ± 2.49-2.0 ± 2.60-5.1 ± 3.52
Day 113-4.7 ± 3.04-2.1 ± 2.40-4.2 ± 3.08-3.2 ± 2.28-3.3 ± 5.69
SecondaryChange From Baseline in Total MG-QoL15r Score at Day 85 and Day 113

The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

Time frame:
Baseline, Day 85 and Day 113
Reported as:
Mean · score on a scale
Change From Baseline in Total MG-QoL15r Score at Day 85 and Day 113
score on a scalePlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Day 85-2.5 ± 2.84-2.9 ± 3.74-6.5 ± 5.66-0.7 ± 4.25-3.5 ± 5.61
Day 113-3.2 ± 3.90-1.6 ± 4.20-4.2 ± 4.32-1.0 ± 2.92-2.5 ± 6.09
SecondaryNumber of Participants With Shift From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification at Day 57

The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

Time frame:
Baseline and Day 57
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification at Day 57
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Improved63747
Same69384
Worsened00101
SecondaryNumber of Participants With Shift From Baseline in MGFA Classification to Day 113

The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

Time frame:
Baseline to Day 113
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in MGFA Classification to Day 113
ParticipantsPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Improved32323
Same65455
Worsened02103
SecondaryChange From Baseline in Total Serum IgG at Day 85 and Day 113

Change from baseline in total serum IgG at Day 85 and Day 113 was analyzed. Blood samples were collected for analysis of total serum IgG.

Time frame:
Baseline, Day 85 and Day 113
Reported as:
Mean · g/L
Change From Baseline in Total Serum IgG at Day 85 and Day 113
g/LPlaceboNipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Day 85-0.5 ± 1.02-1.4 ± 1.93-3.8 ± 1.28-1.2 ± 1.02-5.7 ± 2.30
Day 113-0.6 ± 1.19-0.7 ± 1.48-1.2 ± 0.78-0.7 ± 1.09-2.2 ± 1.73
SecondarySerum Concentrations of Nipocalimab

Serum concentrations of nipocalimab were reported. Concentrations below the lowest quantifiable concentration (\< LLOQ) that is \<0.15 microgram/milliliter (mcg/mL) was treated as zero in calculating the summary statistics.

Time frame:
Baseline (Pre Infusion and Post Infusion), Day 15 (Pre Infusion), Day 29 (Pre Infusion), Day 43 (Pre Infusion), Day 57 (Pre Infusion and Post Infusion) and Day 85
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Serum Concentrations of Nipocalimab
micrograms/milliliter (mcg/mL)Nipocalimab 5 mg/kgNipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Baseline (Pre Infusion)0.0 ± 0.0050.00 ± 0.00.0 ± 0.00.0 ± 0.0
Baseline (Post Infusion)117.75 ± 84.835746.80 ± 47.2141847.50 ± 153.2701325.00 ± 616.443
Day 15 (Pre Infusion)0.0 ± 0.0060.01 ± 0.01027.61 ± 42.16729.30 ± 36.631
Day 29 (Pre Infusion)0.0 ± 0.0040.0 ± 0.00.0 ± 0.072.69 ± 152.058
Day 43 (Pre Infusion)0.0 ± 0.0040.01 ± 0.0130.0 ± 0.066.72 ± 85.919
Day 57 (Pre Infusion)0.0 ± 0.00695.40 ± 301.6810.0 ± 0.044.80 ± 68.560
Day 57 (Post Infusion)49.15 ± 41.507746.50 ± 96.8740.0 ± 0.01827.50 ± 741.052
Day 850.0 ± 0.0070.0 ± 0.00.0 ± 0.00.0 ± 0.004

Adverse events

Collected over Up to Day 113. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/14 (0%)2/14 (14.3%)10/14 (71.4%)
Nipocalimab 5 Milligrams/Kilogram (mg/kg)0/14 (0%)0/14 (0%)12/14 (85.7%)
Nipocalimab 30 mg/kg0/13 (0%)1/13 (7.7%)8/13 (61.5%)
Nipocalimab 60 mg/kg0/13 (0%)0/13 (0%)12/13 (92.3%)
Nipocalimab 60 mg/kg (Q2W)0/14 (0%)0/14 (0%)12/14 (85.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
Musculoskeletal PainMusculoskeletal and connective tissue disorders0/140/141/130/130/14
Ischaemic StrokeNervous system disorders1/140/140/130/130/14
Myasthenia GravisNervous system disorders1/140/140/130/130/14
Most frequent other events
Showing 10 of 102
Most frequent other events
EventPlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)
RashSkin and subcutaneous tissue disorders0/141/140/130/133/14
DiarrhoeaGastrointestinal disorders1/141/141/132/132/14
NasopharyngitisInfections and infestations0/141/141/132/132/14
ArthralgiaMusculoskeletal and connective tissue disorders0/140/140/132/130/14
Musculoskeletal PainMusculoskeletal and connective tissue disorders0/140/140/132/130/14
DizzinessNervous system disorders0/140/141/132/130/14
HeadacheNervous system disorders1/142/141/132/131/14
HypoaesthesiaNervous system disorders0/140/140/132/130/14
Oedema PeripheralGeneral disorders0/140/140/131/132/14
Urinary Tract InfectionInfections and infestations0/140/140/130/132/14

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Categorical
Age, Categorical(Participants)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
<=18 years000000
Between 18 and 65 years8999843
>=65 years6544625
Age, Continuous
Age, Continuous(years)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
Mean57.7 ± 17.8554.8 ± 17.6449 ± 19.5453.1 ± 15.459.9 ± 15.0355 ± 17.07
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
Female8699537
Male6844931
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
American Indian or Alaska Native001001
Asian000000
Black or African American020002
Native Hawaiian or Other Pacific Islander000000
White121212131463
More than one race000000
Unknown or Not Reported000000
Other200002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
Hispanic or Latino413109
Not Hispanic or Latino101310111458
Unknown or Not Reported000101
Region of Enrollment
Region of Enrollment(Participants)PlaceboNipocalimab 5 Milligrams/Kilogram (mg/kg)Nipocalimab 30 mg/kgNipocalimab 60 mg/kgNipocalimab 60 mg/kg (Q2W)Total
BELGIUM100001
CANADA220015
GERMANY131005
ITALY221005
POLAND121318
SPAIN4062315
UNITED KINGDOM000314
UNITED STATES3545825
08

Study locations

61 sites
  • Momenta Investigational Site
    Phoenix, Arizona 85013, United States
  • Momenta Investigational Site
    Tucson, Arizona 85724, United States
  • Momenta Investigational Site
    Los Angeles, California 90048, United States
  • Momenta Investigational Site
    Orange, California 92868, United States
  • Momenta Investigational Site
    Stanford, California 94305, United States
  • Momenta Investigational Site
    Aurora, Colorado 80045, United States
  • Momenta Investigational Site
    New Haven, Connecticut 06511, United States
  • Momenta Investigational Site
    Boca Raton, Florida 33487, United States
  • Momenta Investigational Site
    Maitland, Florida 32751, United States
  • Momenta Investigational Site
    Port Charlotte, Florida 33952, United States
  • Momenta Investigational Site
    Saint Petersburg, Florida 33713, United States
  • Momenta Investigational Site
    Augusta, Georgia 30912, United States
  • Momenta Investigational Site
    Meridian, Idaho 83642, United States
  • Momenta Investigational Site
    Lake Barrington, Illinois 60010, United States
  • Momenta Investigational Site
    Fairway, Kansas 66205, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02114, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02115, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02215, United States
  • Momenta Investigational Site
    Detroit, Michigan 48202, United States
  • Momenta Investigational Site
    East Lansing, Michigan 48824, United States
  • Momenta Investigational Site
    Columbia, Missouri 65212, United States
  • Momenta Investigational Site
    New Brunswick, New Jersey 08550, United States
  • Momenta Investigational Site
    New York, New York 10021, United States
  • Momenta Investigational Site
    Charlotte, North Carolina 28207, United States
  • Momenta Investigational Site
    Durham, North Carolina 27710, United States
  • Momenta Investigational Site
    Raleigh, North Carolina 27607, United States
  • Momenta Investigational Site
    Cincinnati, Ohio 45267, United States
  • Momenta Investigational Site
    Columbus, Ohio 43210, United States
  • Momenta Investigational Site
    Cordova, Tennessee 38106, United States
  • Momenta Investigational Site
    Austin, Texas 78756, United States
  • Momenta Investigational Site
    Round Rock, Texas 78681, United States
  • Momenta Investigational Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Momenta Investigational Site
    Antwerp, 2650, Belgium
  • Momenta Investigational Site
    Bruxelles, 1070, Belgium
  • Momenta Investigational Site
    Edmonton, Alberta T6G 2G3, Canada
  • Momenta Investigational Site
    London, Ontario N6A 5A5, Canada
  • Momenta Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • Momenta Investigational Site
    Quebec City, Quebec G1J 1Z4, Canada
  • Momenta Investigational Site
    Gottingen, Niedersachsen 37075, Germany
  • Momenta Investigational Site
    Düsseldorf, 40225, Germany
  • Momenta Investigational Site
    Gummersbach, 51643, Germany
  • Momenta Investigational Site
    Munster, 48149, Germany
  • Momenta Investigational Site
    Cefalu, 90015, Italy
  • Momenta Investigational Site
    Messina, 98125, Italy
  • Momenta Investigational Site
    Milano, 20133, Italy
  • Momenta Investigational Site
    Krakow, 31-505, Poland
  • Momenta Investigational Site
    Lodz, 90-324, Poland
  • Momenta Investigational Site
    Warsaw, 01-684, Poland
  • Momenta Investigational Site
    Warsaw, 01-868, Poland
  • Momenta Investigational Site
    Barcelona, Catalan 08035, Spain
  • Momenta Investigational Site
    Barcelona, Catalan 08041, Spain
  • Momenta Investigational Site
    Badalona, Cataluna 08036, Spain
  • Momenta Investigational Site
    L'hospitalet De Llobregat, Cataluna 08907, Spain
  • Momenta Investigational Site
    San Sebastian, Gipuzkoa 20014, Spain
  • Momenta Investigational Site
    Madrid, 28007, Spain
  • Momenta Investigational Site
    Madrid, 28040, Spain
  • Momenta Investigational Site
    Sevilla, 41013, Spain
  • Momenta Investigational Site
    Valencia, 46026, Spain
  • Momenta Investigational Site
    Birmingham, B15 2TH, United Kingdom
  • Momenta Investigational Site
    Sheffield, S11 9NE, United Kingdom
  • Momenta Investigational Site
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jun 2020, 14 months.

Results were first posted in Oct 2021, 1 year 4 months after primary completion.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 11, 2018
StartActual
Apr 10, 2019
Primary completionActual
Jun 25, 2020
CompletionActual
Jun 25, 2020
Results first posted
Oct 27, 2021
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03772587
Responsible party
Sponsor
First posted
Dec 11, 2018
Start date
Apr 10, 2019
Primary completion
Jun 25, 2020
Completion
Jun 25, 2020
Results posted
Oct 27, 2021
Last update
Jun 27, 2023

Study contacts

Momenta General Queries
study director · Momenta Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion